A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
Maria Lia PalombaPaola GhioneAnik R PatelMyrna NahasSara BeygiAnthony J HatswellSteve KantersEve H Limbrick-OldfieldSally W WadeMarkqayne D RayJessica OwenSattva S NeelapuJohn GribbenJohn RadfordSabela BobilloPublished in: Expert review of anticancer therapy (2023)
Clinical trials identification: www.clinicaltrials.gov. Identifier is #NCT03105336. This manuscript provides an update to a previously published analysis, using data with a longer minimum follow-up. [1].
Keyphrases
- clinical trial
- acute lymphoblastic leukemia
- acute myeloid leukemia
- electronic health record
- multiple myeloma
- diffuse large b cell lymphoma
- hodgkin lymphoma
- big data
- phase ii
- bioinformatics analysis
- systematic review
- open label
- randomized controlled trial
- double blind
- deep learning
- artificial intelligence
- placebo controlled